Abstract
Myocardial fibrosis commonly occurs in patients with end-stage renal disease (ESRD) and has proven to be an important predictor for cardiovascular events. In experimental settings, angiotensin II type 1 receptor (AT1-R) antagonists have been shown to have anti-fibrotic effects on the myocardium independent of their antihypertensive effects. In this study, to investigate whether the AT1-R antagonist losartan would have such anti-fibrotic effects in patients, we administered losartan or, for purpose of comparison, the angiotensin-converting enzyme enalapril or Ca2+-antagonist amlodipine to patients with ESRD. Thirty-nine ESRD patients with hypertension were randomly assigned to receive losartan (n=13), enalapril (n=13), or amlodipine (n=13). Ultrasonic integrated backscatter (IBS) and serological markers of collagen type I synthesis and degradation were used to assess the degree of myocardial fibrosis just before and after 6 months of treatment. There were no significant differences in antihypertensive effects among the three agents. In the enalapril- and amlodipine-treated groups, the mean calibrated IBS values increased significantly after 6 months of treatment (enalapril: −31.6±1.3 to −29.4±1.2 dB, p=0.011; amlodipine: −30.6±1.4 to −27.2±1.2 dB, p=0.012). However, the mean calibrated IBS values in the losartan-treated group did not increase after 6 months of treatment (−31.2±1.7 to −31.3±1.4 dB, p=0.88). The ratio of the serum concentration of procollagen type I carboxy-terminal peptide to the serum concentration of collagen type I pyridinoline cross-linked carboxy-terminal telopeptide was significantly reduced in the losartan-treated group (42.6±4.6 to 34.4±3.6, p=0.038). The present study indicates that losartan more effectively suppresses myocardial fibrosis in patients with ESRD than does enalapril or amlodipine despite a comparable antihypertensive effect among the three drugs.
Similar content being viewed by others
Article PDF
References
Shinzato T, Nakai S, Akiba T, et al: Report of the annual statistical survey of the Japanese Society for Dialysis Therapy in 1996. Kidney Int 1999; 55: 700–712.
Geerling W, Tufveson G, Broyer M, Brunner FP, Brynger H, Fassbinder W : Combined report on regular dialysis and transplantation in Europe. Proc Eur Dial Transplant Assoc 1983; 17: 52–54.
Amann K, Tyralla K : Cardiovascular changes in chronic renal failure—pathogenesis and therapy. Clin Nephrol 2002; 58 ( Suppl 1): S62–S72.
Matsubara H : Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998; 83: 1182–1191.
Sadoshima J, Izumo S : Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Circ Res 1993; 73: 413–423.
Zhou G, Kandala JC, Tyagi SC, Katwa LC, Weber KT : Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts. Mol Cell Biochem 1996; 154: 171–178.
Dostal DE : Regulation of cardiac collagen: angiotensin and cross-talk with rocal growth factors. Hypertension 2001; 37: 841–844.
Lattanzi F, Bello VD, Picano E, et al: Normal ultrasonic myocardial reflectivity in athletes with increased left ventricular mass: a tissue characterization study. Circulation 1992; 85: 1828–1834.
Lopez B, Gonzalez A, Varo N, Laviades C, Querejeta R, Diez J : Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001; 38: 1222–1226.
Diez J, Laviades C : Monitoring fibrillar collagen turnover in hypertensive heart disease. Cardiovasc Res 1997; 35: 202–205.
Shibasaki Y, Mori Y, Tsutsumi Y, et al: Differential kinetics of circulating angiotensin IV and II after treatment with angiotensin II type 1 receptor antagonist and their plasma levels in patients with chronic renal failure. Clin Nephrol 1999; 51: 83–91.
Sahn DJ, Demaria A, Kisslo J, Weyman A : Recommendations regarding quantitation in M-mode echocardiography: results of survey of echocardiographic measurements. Circulation 1978; 58: 1072–1083.
Schiller NB, Shah PM, Crawford M, et al: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989; 2: 358–367.
Harnett JD, Murphy B, Collingwood P, Purchase L, Kent G, Parfrey PS : The reliability and validity of echocardiographic measurement of left ventricular mass index in hemodialysis patients. Nephron 1993; 65: 212–214.
Ando Y, Yanagiba S, Asano Y : The inferior vena cava diameter as a marker of dry weight in chronic hemodialyzed patients. Artif Organs 1995; 19: 1237–1242.
Langendorf R, Pirani CL : The heart in uremia. Am Heart J 1947; 33: 282–307.
Amann K, Ritz E, Wiest G, Klaus G, Mall G : A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994; 10: 1814–1819.
Wickline SA, Thomas LJ III, Miller JG, et al: The dependence of myocardial ultrasonic integrated backscatter on contractile performance. Circulation 1985; 72: 183–192.
Picano E, Pelosi G, Marzilli M, et al: In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans. Circulation 1990; 81: 58–64.
O'Brien PD, O'Brien WD, Rhyne TL, et al: Relation of ultrasonic backscatter and acoustic propagation of myofibrillar length and myocardial thickness. Circulation 1995; 91: 171–175.
Atgen M, Popp RL : Influence of the myocardial fibers on echocardiographic images. Am J Cardiol 1987; 60: 147–152.
Wickline SA, Verdonk ED, Wong AK, et al: Structural remodeling of human myocardial tissue after infarction: quantification with ultrasonic backsatter. Circulation 1992; 85: 259–268.
Mimbs JW, O'Donnel M, Bauwens D, et al: The dependence of ultrasonic attenuation and backscatter on collagen content in dog and rabbit hearts. Circ Res 1980; 47: 48–58.
Sagar KB, Rhyne TL, Waltier DC, et al: Intramyocardial variability in integrated backscatter: effects of coronary occlusion and reperfusion. Circulation 1987; 75: 436–442.
Nozaki S, DeMaria AN, Helmer GA, et al: Detection of regional left ventricular dysfunction in early pacing-induced heart failure using ultrasonic integrated backscatter. Circulation 1995; 92: 2676–2682.
Masuyama T, Goar FG, Tye TL, et al: Ultrasonic tissue characterization of human hypertrophied hearts in vivo with cardiac cycle-dependent variation in integrated backscatter. Circulation 1989; 80: 925–934.
Feinberg MS, Gussak HM, Davila-Roman VG, et al: Dissociation between wall thickening of normal myocardium and cyclic variation of backscatter during inotropic stimulation. Am J Cardiol 1996; 77: 515–520.
Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Ubago JLM : Losartan-dependent regression myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105: 2512–2517.
Laurent GJ : Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol 251: C1–C9, 1987.
Laragh JH : Renin profiling for diagnosis, risk assessment, and treatment of hypertension. Kidney Int 1993; 44: 1163–1175.
Suzuki J, Matsubara H, Inada M : Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res 1993; 73: 439–447.
Kijima K, Matsubara H, Murasawa S, et al: Mechanical stretch induces enhanced expression of angiotensin II receptor subtypes in neonatal rat cardiac myocytes. Circ Res 1996; 79: 887–897.
Urata H, Healy B, Stewart RW, Bumpus FM, Husain A : Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883–890.
Himmelmann A, Svensson A, Bergbrant A, Hansson L : Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension. J Hum Hypertens 1996; 10: 729–734.
Silberberg JS, Barre PE, Prichard SS, Sniderman AD : Role of anemia in pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am J Cardiol 1989; 64: 222–224.
Martinez-Vea A, Bardaji A, Garcia C, Ridao C, Richart C, Oliver JA : Long-term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis. Am J Kidney Dis 1992; 19: 353–357.
Washio M, Okuda S, Mizoue T, et al: Risk factors for left ventricular hypertrophy in chronic hemodialysis patients. Clin Nephrol 1997; 47: 362–366.
London GM, De Vernejoul MC, Fabiani F, et al: Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients. Kidney Int 1987; 32: 900–907.
Hoieggen A, Alderman M, Kjeldsen S, et al: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041–1049.
Nagahama K, Iseki K, Inoue T, et al: Hyperuricemia and cardiovascular risk factor clustering in a screened cohort in Okinawa, Japan. Hypertens Res 2004; 27: 227–233.
Nagahama K, Inoue T, Iseki K, et al: Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res 2004; 27: 835–841.
Burnier M, Rutschmann B, Nussberger J, et al: Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993; 22: 339–347.
Burnier M, Roch-Ramel F, Brunner HR, et al: Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 1996; 49: 1787–1790.
Ganau A, Devereux RB, Roman MJ, et al: Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19: 1550–1508.
Cannella G, Paoletti E, Delfino R, et al: Regression of left ventricular hypertrophy on hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 1993; 44: 881–886.
Jiang Y, Qu P, Ding Y, et al: The relation between left ventricular geometric patterns and left ventricular midwall mechanics in hypertensive patients. Hypertens Res 2002; 25: 191–195.
Qu P, Ding Y, Xia D, et al: Variations in cardiac diastolic function in hypertensive patients with different left ventricular geometric patterns. Hypertens Res 2001; 24: 601–604.
Takiuchi S, Rakugi H, Fujii H, et al: Carotid intima-media thickness is correlated with impairment of coronary flow reserve in hypertensive patients without coronary artery disease. Hypertens Res 2003; 26: 945–951.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shibasaki, Y., Nishiue, T., Masaki, H. et al. Impact of the Angiotensin II Receptor Antagonist, Losartan, on Myocardial Fibrosis in Patients with End-Stage Renal Disease: Assessment by Ultrasonic Integrated Backscatter and Biochemical Markers. Hypertens Res 28, 787–795 (2005). https://doi.org/10.1291/hypres.28.787
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.28.787
Keywords
This article is cited by
-
Antifibrotic therapies to control cardiac fibrosis
Biomaterials Research (2016)
-
Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease
Nature Reviews Drug Discovery (2016)
-
Treatment of Idiopathic Pulmonary Fibrosis with Losartan: A Pilot Project
Lung (2012)
-
Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide
Kidney International (2008)